- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 15
The Center for Biosimilars® recaps the top news for the week of April 15, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 15.
Number 5: The Community Oncology Alliance (COA) has released a position statement about biosimilars, saying it will work with stakeholders to support the acceptance of these drugs.
Number 4: A pharmacy benfit manager says that the first year of its biosimilar management program has led to strong uptake of Inflectra.
Number 3: The Institute for Clinical and Economic Review will assess rheumatoid arthritis treatments, including biosimilar infliximab.
Number 2: A 2-part proposal argues that biosimilar competition is an economically inefficient way to achieve the goal of lower prices.
Number 1: Health Canada has approved Celltrion and Teva’s biosimilar rituximab, Truxima, for both oncology and rheumatology indications.
Finally, last week, our e-newsletter asked whether you think drug makers will attempt to differentiate their biosimilars through innovation.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
